Consistent with this, clinical data showed that after 16 weeks of GLP-1 receptor agonist treatment, circulating ANGPTL8 levels in T2DM patients were significantly higher than baseline levels [5]. The gene discussed is ANGPTL8; the disease is type 2 diabetes mellitus.